KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Assets Average (2016 - 2025)

Historic Assets Average for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to $2.4 billion.

  • Halozyme Therapeutics' Assets Average rose 1351.3% to $2.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.4 billion, marking a year-over-year increase of 1351.3%. This contributed to the annual value of $2.3 billion for FY2025, which is 2086.14% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Assets Average of $2.4 billion as of Q4 2025, which was up 1351.3% from $2.1 billion recorded in Q3 2025.
  • Halozyme Therapeutics' Assets Average's 5-year high stood at $2.4 billion during Q4 2025, with a 5-year trough of $773.3 million in Q1 2021.
  • For the 5-year period, Halozyme Therapeutics' Assets Average averaged around $1.7 billion, with its median value being $1.8 billion (2022).
  • As far as peak fluctuations go, Halozyme Therapeutics' Assets Average skyrocketed by 11039.28% in 2021, and later crashed by 216.19% in 2023.
  • Halozyme Therapeutics' Assets Average (Quarter) stood at $1.1 billion in 2021, then surged by 61.85% to $1.9 billion in 2022, then fell by 2.16% to $1.8 billion in 2023, then rose by 15.32% to $2.1 billion in 2024, then grew by 13.51% to $2.4 billion in 2025.
  • Its Assets Average was $2.4 billion in Q4 2025, compared to $2.1 billion in Q3 2025 and $2.1 billion in Q2 2025.